This site is intended for Healthcare Professionals only.

MHRA approves new dose for treating alopecia areata


Share post:

The new medication is said to reduce inflammation

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new drug today (1 November) to treat severe alopecia areata.

Litfulo is the new hard capsule medicine with a recommended dosage of just 50 mg per day.

It contains an active ingredient, ritlecitinib, an enzyme inhibitor treatment for patients over 12 years.

Ritlecitinib works by reducing the activity of enzymes in the body called JAK3 and TEC kinases that cause hair follicle inflammation.

This reduction in inflammation leads to hair regrowth in patients with alopecia areata.

Alopecia areata is an autoimmune disease, where the body’s own immune system attacks hair follicles leading to hair loss on the scalp and other parts of the body.

The most common side effects of the medicine include headache, diarrhoea, dizziness, acne, rash, tuberculosis (TB), and shingles.

Pharmacy Business has contacted MHRA for further information.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

RPS joins efforts to boost children’s health in Wales

A group of 20 royal colleges and professional bodies unite to elevate the profile of child health in...

SSPs reactivated for clarithromycin amid surging whooping cough cases

The UK Health Security Agency (UKHSA) has confirmed 2,793 cases of whooping in the first quarter of 2024,...

Insect bites and stings surge: Searches for NHS advice triple

Visit your local pharmacy for advice and treatment of common health conditions, including infected insect bites Insect bites...

RPS Fellowship May 2024 list announced: Benjamin Hannan shines as the youngest Scottish fellow

Hannan joins 783 diverse RPS Fellowship members alongside other new 19 members announced  Benjamin Hannan, director of reform and...